TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01810809

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: articular lavage with saline injection
Description: Patients will receive articular lavage with saline injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: articular lavage with saline injection
Description: Patients will receive articular lavage with saline injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: articular lavage with saline injection
Description: Patients will receive articular lavage with saline injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: articular lavage with saline injection
Description: Patients will receive articular lavage with saline injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 ampoule of Hylan GF-20
Description: Patients will receive viscosupplementation with 2ml (1 ampoule) of Hylan GF-20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 ampoules of Hylan GF-20
Description: Patients will receive viscosupplementation with 4ml (2 ampoules) of Hylan GF-20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 ampoules of Hylan GF-20
Description: Patients will receive viscosupplementation with 6ml (3 ampoules) of Hylan GF-20
Study: NCT04288024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight-shifting training
Description: Postural task: Participants are standing with their weak side on the force plate. During the task, they wight-shift from side to side ranging from 10 to 90 percent of their body weight.~Suprapostural task: Participants hold a tray with their arms beside the body, 90 degrees of elbow flexion. They rotate the tray left and right for 45 degrees respectively.~During their task, participants should weight-shift and rotate the tray at the same time.
Study: NCT03382925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 2 mL lidocaine to be used as steroid diluent in group #1 cervical interlaminar procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: 2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: 2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 2 mL of normal saline to be used as steroid diluent in group #2 cervical interlaminar procedure.
Study: NCT04665063

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Auto CAR-T
Description: Biological: Auto CAR-T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide,Fludarabine
Description: Drug: Cyclophosphamide,Fludarabine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Leukapheresis
Study: NCT01780870

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss group (Full meal replacement products)
Description: In the intervention arm of this non randomized, open label study to assess the effects of weight loss on insulin sensitivity and leptin tolerance subjects will use full meal replacement products (1280-1320kcal/day). Subjects will be on the full meal replacement products only, for the first 12 weeks, between 13 to 19 weeks they will be transitioned to regular food, from 19 weeks and going forward they will be on chronic maintenance phase
Study: NCT01334632

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous interscalene block
Description: The continuous interscalene block will be performed with ultrasound 30 minutes before the intervention.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PCA morphine
Description: Postoperative with iv self-administration of morphine
Study: NCT01602419

Intervention type: OTHER
Intervention: Patients using Wilate as standard of care
Description: Patients with von Willebrand Disease using Wilate for a period of 2 years.
Study: NCT01773590

Intervention type: OTHER
Group type: OTHER
Intervention: Rhinovirus Infection

Intervention type: OTHER
Group type: OTHER
Intervention: Rhinovirus Infection
Study: NCT02503293

Intervention type: DEVICE
Group type: OTHER
Intervention: Chrono Super PID then Generic Syringe-Gammanorm
Description: Each patient will receive the study treatment of Gammanorm using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• pump and then syringe~The use of automatic, programmable, compact pumps (such as CRONO SUPER PID) allows patients to remain mobile without interrupting their activities. Patients can infuse several sites simultaneously with infusion rates of up to 40 mL/h at 2 to 4 sites (abdomen, thighs, upper arms, lower back).~Rapid and manual administration of SCIg using a syringe could therefore represent an alternative method by decreasing the duration of administration (around 10 minutes per injection at 1 or 2 sites simultaneously). The injection is self-administered by the patient. The infusion rate usually is 1 to 2 mL/min. The use of low viscosity products could facilitate injection

Intervention type: DEVICE
Group type: OTHER
Intervention: Generic Syringe then Chrono Super PID-Gammanorm
Description: Each patient will receive the study treatment using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• syringe and then pump.~The use of automatic, programmable, compact pumps (such as CRONO SUPER PID) allows patients to remain mobile without interrupting their activities. Patients can infuse several sites simultaneously with infusion rates of up to 40 mL/h at 2 to 4 sites (abdomen, thighs, upper arms, lower back).~Rapid and manual administration of SCIg using a syringe could therefore represent an alternative method by decreasing the duration of administration (around 10 minutes per injection at 1 or 2 sites simultaneously). The injection is self-administered by the patient. The infusion rate usually is 1 to 2 mL/min. The use of low viscosity products could facilitate injection
Study: NCT00487565

Intervention type: DEVICE
Group type: OTHER
Intervention: Total knee arthroplasty
Description: Total knee arthroplasty using a posterior stabilized implant
Study: NCT03472105

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: New Nordic Renal Diet
Description: One week ingesting a phosphorus reduced diet containing a total of 850 mg of phosphorus/day compared to one week of a habitual diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: New Nordic Renal Diet
Description: One week ingesting a phosphorus reduced diet containing a total of 850 mg of phosphorus/day compared to one week of a habitual diet
Study: NCT01926912

Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Participants prescribed with paliperidone palmitate by the treating physician as per local labeling information in the hospital setting will be observed and data will be collected.
Study: NCT03324178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Description: Sixteen 30-minute sessions of neurofeedback training over four weeks: 7 x 3-minute blocks of training flanked by a 3-minute resting state block with eyes-open.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video game
Description: Sixteen 30-minute sessions of video game playing over four weeks: 7 x 3-minute blocks flanked by a 3-minute seated relaxation.
Study: NCT03961425

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NO CO2
Description: Traditional mechanical Deairing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 Cannula
Description: NON specific, low cost delivery system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 Cardia
Description: Specific Commercial CO2 Diffuser
Study: NCT01056666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conveen Optima is a urisheath to be used together with a collecting bag for urine
Description: Conveen optima urisheath is intended to be used together with a collecting bag for urine and to be changed on a daily basis

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: absorbent protection
Description: The patient use his usual absorbent protection (same brand), and change it when needed
Study: NCT01173211

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone, Agriflu and Fluarix do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone, Agriflu and Fluarix do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber..

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone®, Agriflu® and Fluarix® do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber.
Study: NCT04813081

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free Gingival Graft
Description: In the recipient area, a half-thickness flap with two vertical incision widths was removed with a horizontal incision with 15C blades from the mucogingival junction. The recipient site was determined such that one or two teeth or one tooth extends into the mesial and distal regions of the tooth. Muscle attachments were dissected and FGG was placed on recipient bed and non-resorbable monofilament sutures were used for fixing the four corners of the graft.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free Gingival Graft
Description: In the recipient area, a half-thickness flap with two vertical incision widths was removed with a horizontal incision with 15C blades from the mucogingival junction. The recipient site was determined such that one or two teeth or one tooth extends into the mesial and distal regions of the tooth. Muscle attachments were dissected and FGG was placed on recipient bed and non-resorbable monofilament sutures were used for fixing the four corners of the graft.
Study: NCT02642367

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath videolaryngoscope
Description: without use of stylet

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath videolaryngoscope with Intubating stylet (Mallinckrodt)
Description: use of stylet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium
Description: tracehal intubation was performed 2 min after rocuronium injection with McGrath videolaryngoscope

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rocuronium
Description: tracehal intubation was performed 2 min after rocuronium injection with McGrath videolaryngoscope
Study: NCT00940693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: duloxetine
Description: 60 mg capsule once per day for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one capsule of placebo taken one a day for 6 weeks
Study: NCT03839121

Intervention type: DEVICE
Intervention: Cardiac Resynchronization Therapy (CRT)
Description: Observation and documentation of CRT patients
Study: NCT01372033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: 18 sessions of CBT, twice weekly
Study: NCT02442128

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol /Fentanyl
Description: fentanyl 2 μg/kg and propofol 2 mg/kg Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol /Fentanyl
Description: fentanyl 2 μg/kg and propofol 2 mg/kg Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
Study: NCT02813460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation H1 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
Study: NCT02442128

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl / propofol
Description: fentanyl 2 μg/kg and propofol 3 mg/kg. Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
Study: NCT02695459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatinum and everolimus
Description: Cisplatinum : 75 mg/m2 days 1,iv Everolimus : 7.5 mg daily: days 1-21 orally
Study: NCT01372033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: 18 sessions with goals groups drug testing
Study: NCT01517880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sialic Acid Extended Release (SA-ER)
Description: SA-ER will be administered in doses of 3000mg per day or 6000mg per day
Study: NCT03563144

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6207
Description: CEA yeast vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301
Description: Brachyury yeast vaccine
Study: NCT03355027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 MG/ML
Description: Dosing to be performed by subcutaneous injection in clinic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe 10Mg Tablet
Description: Patients will be instructed to take once daily at night.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40Mg Tablet
Description: Patients will be instructed to take once daily at night. Atorvastatin will be the preferred statin option for those with eGFR \< 60 ml/min/1.73m2. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
Study: NCT03545828

Intervention type: DIAGNOSTIC_TEST
Intervention: Multi-channel aEEG monitoring
Description: 18 channel aEEG monitoring in comatose TTM-treated patients

Intervention type: DIAGNOSTIC_TEST
Intervention: Multi-channel aEEG monitoring
Description: 18 channel aEEG monitoring in comatose TTM-treated patients
Study: NCT03100422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARMin
Description: arm therapy robot

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy
Description: bilateral arm training
Study: NCT03494894

Intervention type: DIAGNOSTIC_TEST
Intervention: Middle meatus aspirations and sputum
Description: Bacterial genotype sequencing analysis will be performed in patients with bacteriological concordance between upper and lower airways.
Study: NCT03355027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 40Mg Tablet
Description: Patients will be instructed to take once daily at night. Atorvastatin will be the preferred statin option for those with eGFR \< 60 ml/min/1.73m2. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
Study: NCT03563144

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK
Description: NK-92 \[CD16.158V, ER IL-2\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin
Study: NCT00612898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apricitabine
Description: 800mg BID apricitabine orally for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamivudine
Description: 150mg BID lamivudine orally for 48 weeks
Study: NCT03748043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: lactoferrin 100 mg per day plus ferric hydroxide polymaltose 6 mg /kilogram of Elemental iron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Hydroxide Polymaltose
Description: group 2 will receive ferric hydroxide polymaltose 6 mg /kilogram of elemental iron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Hydroxide Polymaltose
Description: group 2 will receive ferric hydroxide polymaltose 6 mg /kilogram of elemental iron
Study: NCT01197443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-only Group
Description: Parent-only group will include the same skills and techniques to promote weight loss as given to the parent + child group, but the information will be delivered only to the parent. Parent group will be compared to the parent group of the parent + child treatment arm. The focus will be on implementing skills learned to assist the child in weight management. The treatment length is set for 12 weekly meetings and bi-monthly meetings during months 4 and 5. Each group session will be 60-min including weigh-ins. Group meetings focus on behavior change, weight loss, healthy eating and activity for the overweight child and parent.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent + Child Group
Description: The treatment for participants in the parent + child group will be administered in two separate groups, one for the parents and one for the child. Treatment will include the same skills and techniques to promote weight loss as given to the parent-only group, but the information will be delivered to both the parent and child. The treatment length, session schedule, treatment content and follow-up assessments are same as the parent-only group.
Study: NCT02554279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: menotropin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant FSH
Study: NCT00950261

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tri-weekly cisplatin
Description: cisplatin 75mg/m2 every 3 weeks, intravenous, 3 cycles
Study: NCT00475423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 1000mg iv on days 1 and 15
Study: NCT02385227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exclusive blu™ e-cigarette A1
Description: Classic Tobacco rechargeable e cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exclusive blu™ e-cigarette A2
Description: Magnificent Menthol rechargeable e cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exclusive blu™ e-cigarette A3
Description: Cherry Crush rechargeable e cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual blu™ e-cigarette and usual brand B1
Description: Classic Tobacco rechargeable e cigarette and a usual brand combustible cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual blu™ e-cigarette and usual brand B2
Description: Magnificent Menthol rechargeable e cigarette and a usual brand combustible cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual blu™ e-cigarette and usual brand B3
Description: Cherry Crush rechargeable e cigarette and a usual brand combustible cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine product cessation C
Description: Nicotine cessation
Study: NCT01133028

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral contingency management
Description: Teachers will learn to use reinforcements and response cost procedures to encourage children's display of prosocial behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral contingency management
Description: Teachers will learn to use reinforcements and response cost procedures to encourage children's display of prosocial behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tolerance training
Description: Teachers will be instructed in procedures to encourage the peer group to be accepting of children with ADHD.
Study: NCT01492543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur Gimeracil Oteracil Potassium Capsule
Description: Aiyi® (Tegafur Gimeracil Oteracil Potassium Capsule; T25mg,G7.25mg,O24.5mg\*42 capsules/box), manufactured by Jiangsu Hengrui Medicine Co., Ltd.,
Study: NCT01331018

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow harvest

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetically Engineered Hematopoietic Stem Progenitor Cells
Description: Undergo infusion of genetically modified hematopoietic progenitor cell therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO